1. Home
  2. SQNS vs GANX Comparison

SQNS vs GANX Comparison

Compare SQNS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SQNS
  • GANX
  • Stock Information
  • Founded
  • SQNS 2003
  • GANX 2017
  • Country
  • SQNS France
  • GANX United States
  • Employees
  • SQNS N/A
  • GANX N/A
  • Industry
  • SQNS Semiconductors
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SQNS Technology
  • GANX Health Care
  • Exchange
  • SQNS Nasdaq
  • GANX Nasdaq
  • Market Cap
  • SQNS 46.5M
  • GANX 53.8M
  • IPO Year
  • SQNS 2011
  • GANX 2021
  • Fundamental
  • Price
  • SQNS $5.40
  • GANX $1.86
  • Analyst Decision
  • SQNS Strong Buy
  • GANX Strong Buy
  • Analyst Count
  • SQNS 1
  • GANX 5
  • Target Price
  • SQNS $7.50
  • GANX $8.20
  • AVG Volume (30 Days)
  • SQNS 10.1M
  • GANX 309.6K
  • Earning Date
  • SQNS 08-22-2025
  • GANX 08-07-2025
  • Dividend Yield
  • SQNS N/A
  • GANX N/A
  • EPS Growth
  • SQNS N/A
  • GANX N/A
  • EPS
  • SQNS 2.16
  • GANX N/A
  • Revenue
  • SQNS $38,858,000.00
  • GANX N/A
  • Revenue This Year
  • SQNS N/A
  • GANX N/A
  • Revenue Next Year
  • SQNS $93.87
  • GANX N/A
  • P/E Ratio
  • SQNS $2.08
  • GANX N/A
  • Revenue Growth
  • SQNS 40.06
  • GANX N/A
  • 52 Week Low
  • SQNS $0.95
  • GANX $0.89
  • 52 Week High
  • SQNS $5.83
  • GANX $3.19
  • Technical
  • Relative Strength Index (RSI)
  • SQNS 87.95
  • GANX 53.85
  • Support Level
  • SQNS $1.34
  • GANX $1.70
  • Resistance Level
  • SQNS $2.68
  • GANX $1.84
  • Average True Range (ATR)
  • SQNS 0.52
  • GANX 0.16
  • MACD
  • SQNS 0.29
  • GANX 0.01
  • Stochastic Oscillator
  • SQNS 76.77
  • GANX 62.75

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: